ChromaDex prepares to report quarterly earnings with analysts expecting break-even results
ChromaDex is set to announce its quarterly earnings on October 31, 2024. Analysts expect the company to report an earnings per share (EPS) of $0.00. Last quarter, ChromaDex beat estimates by $0.02, resulting in a 9.51% share price increase. Analysts rate ChromaDex as a "Buy," with a one-year price target of $6.00, suggesting a potential upside of 65.75%. In comparison, peers Codexis, Lifecore Biomedical, and Personalis have higher price targets, indicating stronger expected growth. ChromaDex leads its peers in revenue growth at 11.89% and gross profit margin, but has the lowest return on equity. The company focuses on healthy aging and is known for its NAD+ precursor, Niagen.